MHRA Clears First Oral IL-23 Pill for Psoriasis

MHRA has approved icotrokinra, brand name Icotyde, for moderate-to-severe plaque psoriasis — a once-daily oral tablet that selectively blocks the IL-23 receptor, in a drug class where every approved option until now has been an injectable. The UK regulator's approval, dated 23 October 2026, covers Janssen-Cilag's (Johnson & Johnson) product for adults and adolescents aged 12 and older weighing at least 40 kilograms who are candidates for systemic therapy, built on four Phase 3 trials spanning roughly 2,500 patients.

A biologic-grade target, in a pill

IL-23 has been a validated psoriasis target for years — AbbVie's Skyrizi (risankizumab) and Bristol Myers Squibb's Sotyktu (deucravacitinib, which works further downstream in the same pathway) are both already on the market. What MHRA's approval changes is the delivery mechanism. Icotrokinra is described by Janssen and corroborated by independent trade coverage as a targeted oral peptide: a molecule engineered to achieve the receptor selectivity of a biologic while being taken as a once-daily 200 mg tablet rather than injected. For a drug class whose adoption has always run into a basic practical ceiling — how many patients will self-inject long-term — an oral option targeting the same receptor is a genuine mechanism-of-administration shift, not just another label expansion.

The evidence, and where it reaches

MHRA's approval rests on four Phase 3 trials covering approximately 2,500 patients, all four meeting superiority over placebo at week 16. Within that total, 72 patients were adolescents aged 12 to under 18 — a small but explicit cohort that let MHRA extend the approved indication down to age 12 in patients weighing at least 40 kg, rather than approving only an adult population and leaving pediatric dermatologists to prescribe off-label. The company co-developed icotrokinra with Protagonist Therapeutics and has projected peak sales around $5 billion across multiple indications being studied beyond psoriasis, a figure that signals how central this molecule is to the sponsor's pipeline rather than a one-off label.

Approved does not mean funded

MHRA's marketing authorisation is a safety-and-efficacy determination; it says nothing about whether the NHS will pay for the drug, on what patients, or on what timeline. That question runs through a separate process — a National Institute for Health and Care Excellence (NICE) technology appraisal — which was still under way as of this approval. Market-access and reimbursement teams tracking icotrokinra's UK rollout need to watch NICE's output as a distinct event from MHRA's approval date, not assume one follows automatically or quickly from the other. In the meantime, MHRA will monitor the drug's safety through its Yellow Card adverse-event reporting scheme, standard for any newly authorised medicine, with the full product information — the Summary of Product Characteristics and Patient Information Leaflet — due on the MHRA Products website within seven days of the approval.

• Dosing: 200 mg, taken orally, once daily.
• Indication: moderate-to-severe plaque psoriasis, patients 12 and older weighing at least 40 kg, candidates for systemic therapy.
• Regulatory sequence: first approved in the United States earlier in 2026; the European Commission approved it 21 September 2026; MHRA approved it in the UK 23 October 2026 — a standalone post-Brexit licensing decision, separate from the EU's.
• What is still open: the NICE technology appraisal that will determine NHS funding and access timing.

Frequently asked questions

What did MHRA approve?

Icotrokinra hydrochloride, brand name Icotyde, from Janssen-Cilag Ltd (Johnson & Johnson), for moderate-to-severe plaque psoriasis in adults and adolescents aged 12 and older weighing at least 40 kg who are candidates for systemic therapy. MHRA's approval is dated 23 October 2026.

What is icotrokinra, and how is it different from existing IL-23 drugs?

It is a 200 mg once-daily oral tablet that selectively blocks the IL-23 receptor. Existing IL-23-targeting therapies for psoriasis, including AbbVie's Skyrizi, are injectable biologics; icotrokinra is described as a targeted oral peptide, administered as a pill rather than an injection.

What evidence supported the approval?

Four Phase 3 trials covering roughly 2,500 patients in total, including 72 adolescents aged 12 to under 18. All four trials showed statistical superiority over placebo at week 16, per MHRA's and Janssen's own disclosures.

Does this approval mean the drug is funded on the NHS?

No. MHRA's marketing authorisation is separate from NHS funding, which runs through a National Institute for Health and Care Excellence (NICE) technology appraisal. That appraisal was still ongoing as of this approval, and its outcome will determine NHS funding and access timing independent of the MHRA decision.